Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$50.4M in Q4 2021 → $9.61M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| RP Recursion Pharmaceuticals In | 100.0% | Trimmed 50% | 903,400 | $9.61M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RP Recursion Pharmaceuticals In | Trimmed | −903,400 | −$9.61M | 100.0% |
| Z Zymergen Inc | Exited | −1,513,727 | −$1.86M | — |
quarter ended June 30, 2022 · filed August 15, 2022
No position changes this quarter.
quarter ended March 31, 2022 · filed May 16, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gitlab Inc | Exited | −107,357 | −$9.34M | — |
Loading...
